Friday, July 10, 2026

Drug profile · INN

iodixanol

iodixanol (VISIPAQUE 270) is a diagnostic agent. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — iodixanol
US status
approved
Class
Route
INJECTION
Patents
0
Programs
3
Data quality
0.84

Quick answer

iodixanol (VISIPAQUE 270) is a diagnostic agent. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN iodixanol
Brand VISIPAQUE 270
Mechanism Diagnostic agent
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. VISIPAQUE d’I/mL for Knee OsteoArthritis Phase 3 · PARItec · Knee OsteoArthritis
  2. Ultravist /ml soluzione iniettabile for breast pathology Phase 2 · Telethon Foundation · breast pathology
  3. iodixanol Approved · First People's Hospital · Kidney Failure, Chronic

Frequently asked questions

What is iodixanol?

iodixanol (VISIPAQUE 270) is a diagnostic agent. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for iodixanol?

VISIPAQUE 270 is a marketed brand name for iodixanol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of iodixanol?

iodixanol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.